11.77

11.13% 1.17

Artiva Biotherapeutics Inc (ARTV)

Overview News Price History Discussions Forecast

Artiva Biotherapeutics Inc stock is traded at $11.77, with a volume of 123.80K. It is up +11.13% in the last 24 hours and up +61.59% over the past month. Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Previous Close:

$10.60

Open:

$11.31

24h Volume:

123.80K

Relative Volume:

0.56

Market Cap:

$291.04M

Revenue:

$251.00K

Net Income/Loss:

$-83.87M

P/E Ratio:

-3.4306

EPS:

-3.4309

Net Cash Flow:

$-79.34M

1W Performance:

+35.09%

1M Performance:

+61.59%

6M Performance:

+242.44%

1Y Performance:

+513.54%

1-Day Range:

$11.00

$12.09

1-Week Range:

$8.75

$12.09

52-Week Range:

$1.47

$14.53

Artiva Biotherapeutics Inc Stock (ARTV) Company Profile

Name

Artiva Biotherapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (615)

Phone

(858) 267-4467

Address

5505 MOREHOUSE DRIVE, SAN DIEGO

Employee

104

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

ARTV's Discussions on Twitter

Compare ARTV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARTV Artiva Biotherapeutics Inc	11.78	262.00M	251.00K	-83.87M	-79.34M	-3.4309
VRTX Vertex Pharmaceuticals Inc	425.05	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	717.53	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	805.51	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.06	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.37	33.06B	5.36B	287.73M	924.18M	2.5229

Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-11-25	Resumed	H.C. Wainwright	Buy
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Initiated	Jefferies	Buy
Aug-13-24	Initiated	Needham	Buy
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Wedbush	Outperform

View All

Artiva Biotherapeutics Inc Stock (ARTV) Latest News

May 05, 2026

Why Artiva Bio (ARTV) could be the turning point you've been waiting for (Gains) 2026-05-05Technical Analysis - Newser

May 05, 2026

May 04, 2026

Artiva Biotherapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView

May 04, 2026

Apr 30, 2026

Artiva Biotherapeutics | 10-K/A: Annual report (Amendment) - Moomoo

Apr 30, 2026

Executive pay and ownership detailed in Artiva Biotherapeutics (NASDAQ: ARTV) 10-K/A - Stock Titan

Apr 30, 2026

Apr 28, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 28, 2026

Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

Apr 28, 2026

Apr 24, 2026

Deep B-Cell Depletion: The Next Wave In Autoimmune Diseases With Artiva's AlloNK In Focus - RTTNews

Apr 24, 2026

Apr 22, 2026

Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm

Apr 22, 2026

Apr 21, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 21, 2026

Apr 20, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 20, 2026

Apr 17, 2026

Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Apr 17, 2026

Apr 15, 2026

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham - MarketBeat

Apr 15, 2026

ARTV: Advancing scalable NK cell therapy for RA, targeting deep, durable responses in refractory patients - TradingView

Apr 15, 2026

Apr 12, 2026

Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen - MarketBeat

Apr 12, 2026

Apr 10, 2026

Whale Trades: Is Blend Labs Inc backed by strong institutional buying2026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm

Apr 09, 2026

Apr 08, 2026

Can Artiva Bio (ARTV) Stock Reach New Highs | Price at $6.37, Down 4.50%Crowd Breakout Signals - Newser

Apr 08, 2026

Apr 06, 2026

Should I Buy Artiva Bio (ARTV) Stock Now | Price at $7.29, Up 8.16%Expert Stock Picks - Newser

Apr 06, 2026

Apr 04, 2026

ARTV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen - MarketBeat

Apr 04, 2026

Apr 03, 2026

ARTV Stock Analysis: Bearish Pressure Amid Market Decline - Newser

Apr 03, 2026

Apr 02, 2026